Bioceres Crop Solutions Corp.

NasdaqGS:BIOX Stock Report

Market Cap: US$440.0m

Bioceres Crop Solutions Valuation

Is BIOX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIOX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$3.59
Fair Value
95.0% overvalued intrinsic discount
4
Number of Analysts

Below Fair Value: BIOX ($7) is trading above our estimate of fair value ($3.59)

Significantly Below Fair Value: BIOX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOX?

Key metric: As BIOX is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIOX. This is calculated by dividing BIOX's market cap by their current revenue.
What is BIOX's PS Ratio?
PS Ratio1x
SalesUS$441.27m
Market CapUS$439.97m

Price to Sales Ratio vs Peers

How does BIOX's PS Ratio compare to its peers?

The above table shows the PS ratio for BIOX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
IPI Intrepid Potash
1.6x4.0%US$332.7m
UAN CVR Partners
1.7xn/aUS$870.7m
AVD American Vanguard
0.3x4.0%US$174.7m
MULG Muliang Viagoo Technology
4.1xn/aUS$49.1m
BIOX Bioceres Crop Solutions
1x9.6%US$440.0m

Price-To-Sales vs Peers: BIOX is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does BIOX's PS Ratio compare vs other companies in the US Chemicals Industry?

15 CompaniesPrice / SalesEstimated GrowthMarket Cap
KOP Koppers Holdings
0.3x1.8%US$618.00m
MATV Mativ Holdings
0.3x1.6%US$521.08m
TSE Trinseo
0.04x4.1%US$145.50m
ALTO Alto Ingredients
0.1x3.1%US$125.70m
BIOX 1.0xIndustry Avg. 1.3xNo. of Companies15PS01.22.43.64.86+
15 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BIOX is good value based on its Price-To-Sales Ratio (1x) compared to the US Chemicals industry average (1.3x).

Price to Sales Ratio vs Fair Ratio

What is BIOX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: BIOX is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIOX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.00
US$11.88
+69.8%
12.0%US$13.00US$9.50n/a4
Jan ’26US$6.08
US$12.13
+99.4%
12.5%US$13.00US$9.50n/a4
Dec ’25US$7.12
US$12.13
+70.3%
12.5%US$13.00US$9.50n/a4
Nov ’25US$6.49
US$12.40
+91.1%
9.7%US$13.00US$10.00n/a5
Oct ’25US$7.86
US$13.50
+71.8%
9.4%US$16.00US$12.50n/a5
Sep ’25US$10.64
US$19.00
+78.6%
18.8%US$25.00US$15.00n/a5
Aug ’25US$10.81
US$19.00
+75.8%
18.8%US$25.00US$15.00n/a5
Jul ’25US$11.13
US$20.25
+81.9%
15.4%US$25.00US$17.00n/a4
Jun ’25US$11.78
US$20.25
+71.9%
15.4%US$25.00US$17.00n/a4
May ’25US$11.66
US$20.25
+73.7%
15.4%US$25.00US$17.00n/a4
Apr ’25US$12.62
US$20.25
+60.5%
15.4%US$25.00US$17.00n/a4
Mar ’25US$13.36
US$20.40
+52.7%
13.7%US$25.00US$17.00n/a5
Feb ’25US$13.25
US$21.20
+60.0%
22.2%US$28.00US$15.00n/a5
Jan ’25US$13.73
US$21.20
+54.4%
22.2%US$28.00US$15.00US$6.085
Dec ’24US$12.36
US$21.20
+71.5%
22.2%US$28.00US$15.00US$7.125
Nov ’24US$10.36
US$22.10
+113.3%
20.1%US$28.00US$15.00US$6.495
Oct ’24US$11.29
US$24.30
+115.2%
22.4%US$31.00US$15.00US$7.865
Sep ’24US$12.06
US$25.30
+109.8%
23.4%US$31.00US$15.00US$10.645
Aug ’24US$12.71
US$25.30
+99.1%
23.4%US$31.00US$15.00US$10.815
Jul ’24US$13.36
US$25.30
+89.4%
23.4%US$31.00US$15.00US$11.135
Jun ’24US$12.20
US$25.30
+107.4%
23.4%US$31.00US$15.00US$11.785
May ’24US$11.17
US$25.30
+126.5%
23.4%US$31.00US$15.00US$11.665
Apr ’24US$11.61
US$27.05
+133.0%
12.5%US$31.00US$22.50US$12.625
Mar ’24US$11.50
US$27.05
+135.2%
12.5%US$31.00US$22.50US$13.365
Feb ’24US$12.49
US$26.45
+111.8%
10.7%US$30.00US$22.50US$13.255
Jan ’24US$12.03
US$26.45
+119.9%
10.7%US$30.00US$22.50US$13.735
Analyst Price Target
Consensus Narrative from 4 Analysts
US$11.88
Fair Value
41.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 22:29
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioceres Crop Solutions Corp. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Austin MoellerCanaccord Genuity
Benjamin KlieveLake Street Capital Markets, LLC